Eli Lilly's stock performance has caught the attention of Morgan Stanley analysts, leading to speculation about its potential to become the first U.S. company outside of the tech-dominated Magnificent Seven to reach a $1 trillion market value. This comes as Morgan Stanley raised its price target for Eli Lilly to a Street High of $950 from $805, reiterating an overweight rating on the stock. The firm attributes this potential to Eli Lilly's promising outlook, particularly in the weight loss market, with analysts seeing upside to the company's 2025 and beyond estimates, partly due to the impact of #Mounjaro.
$LLY Lilly’s Gains Have Morgan Stanley Asking $1 Trillion Question. $XBI #Mounjaro https://t.co/WJXIPJDkPr
Eli Lilly Stock’s Upside Prompts Morgan Stanley to Ask if It Can Reach $1 Trillion https://t.co/SVf7jaC2Wp
Morgan Stanley ponders if Eli Lilly could be the first $1 trillion pharma stock on weight loss boom https://t.co/hfwcLflJXN
$LLY Morgan Stanley reiterates Eli Lilly as overweight Morgan Stanley raised its price target on the stock to $950 per share from $805 and says it can be the first $1 trillion company. “Reiterate OW rating on LLY as we see upside to 2025+ estimates (and refresh our Bull…
$LLY PT raised to Street High $950 at Morgan Stanley. $XBI https://t.co/IpdyZ7YPS6
Eli Lilly’s relentless stock records have Morgan Stanley analysts musing whether it will become the first US company outside of the Magnificent Seven to reach $1 trillion market value https://t.co/FEhZ3nNwEY